Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Flamma SpA","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Flamma, Gilead Continue Mfg. Partnership for Veklury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Flamma SpA

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Flamma has entered into an agreement with Gilead earlier this year to be part of the network of manufacturers contributing to the Veklury® supply chain. Flamma will continue to use its sites in Italy and China to support Gilead in supplies of the drug for Covid-19.

            Lead Product(s): Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Veklury

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 05, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY